Metformin to slow lung decline in IPF
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether the diabetes drug metformin can slow down the worsening of breathing in people with IPF. If you have IPF and meet certain health criteria, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of idiopathic pulmonary fibrosis (IPF) by a doctor.
- You must be at least 40 years old.
- Your blood sugar level (HbA1c) must be less than 9%.
- You must not have taken metformin in the past 3 months.
- You cannot need more than 2 liters of continuous oxygen per minute at rest.
- You must be willing to avoid pregnancy or use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
This study tests whether metformin, a common diabetes drug, can slow down the aging of the lungs and improve COPD symptoms. If you have COPD and meet the specific lung function and smoking history criteria, you might be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.